Ackman boosts stake in drugmaker Valeant
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Buy Valeant Pharmaceuticals (VRX) Ahead of Investor Day Catalyst - Guggenheim
November 24, 2015 8:02 AM ESTGuggenheim analyst Louise Chen reiterated a Buy rating and $195 on Valeant Pharmaceuticals (NYSE: VRX) saying the stock has bottomed and multiple expansion will drive shares higher. Chen recommends buying ahead of the December 16, 2015 investor day catalyst.
"Concerns regarding high-priced drugs and specialty pharmacies have weighed on VRX shares since mid-September,... More
